Search

Your search keyword '"GREEN, LOUISA"' showing total 28 results
Start Over Author "GREEN, LOUISA"
28 results on '"GREEN, LOUISA"'

1. Teaching Assistants' experiences of supporting pupils in a mainstream primary school context : an interpretative phenomenological analysis

Author

Elston-Green, Louisa and Tarleton, Beth

Subjects
371.9
Abstract

Teaching Assistants (TAs) can play an important role in the educational support for pupils with Special Educational Needs (SEN). The broad aim of this study was to understand TAs’ experiences of supporting pupils in a mainstream primary setting. Data was gathered using semi-structured interviews and Interpretative Phenomenological Analysis (IPA) was employed as a methodological framework and a method of analysis. Three overarching themes were identified as important to participants’ experiences of supporting pupils, these included: Being a TA and role Perceptions; Applying Learning to Practice; and TA Experiences and Perceptions of Inclusion. The findings suggested that TAs perceived the key aim of their role as helping the pupil to cope with the mainstream environment, and they acted either as a bridge or a gap filler. This raised questions as to why the gap existed in the first place, and implications for the TA role are discussed with reference to the agenda for inclusive education. Findings also suggested that training was generally useful for TA practice. Personal values also influenced practice and how TAs applied learning from training to practice. This has not been identified in previous research and models of TA practice (Webster et al., 2011), and so this offers a unique contribution to the existing research base. Considerable variation existed between participant accounts regarding their working relationship with the class teacher and the level of responsibility they took for the pupil, which was influenced by the TAs’ own goals, values, and personal status. Findings highlighted that some TAs felt excluded and marginalised within the wider system in which they worked. Findings also highlighted that although TAs may be influenced by wider systemic factors, as suggested in previous models, they are also active agents in their own practice. Implications for Educational Psychology practice are discussed.

Published
2017

3. AKT inhibition generates potent polyfunctional clinical grade AUTO1 CAR T-cells, enhancing function and survival

Author

Mehra, Vedika, primary, Agliardi, Giulia, additional, Dias Alves Pinto, Juliana, additional, Shafat, Manar S, additional, Garai, Amaia Cadinanos, additional, Green, Louisa, additional, Hotblack, Alastair, additional, Arce Vargas, Fred, additional, Peggs, Karl S, additional, van der Waart, Anniek B, additional, Dolstra, Harry, additional, Pule, Martin A, additional, and Roddie, Claire, additional

Published
2023
Full Text
View/download PDF

5. Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial

Author

Grisoni, Jeannie, Byrne, Carolyn, Davenport, Katy, Neoh, Sandra, Gougeon, Claire, Oldford, Carolyn, Young, Catherine, Green, Louisa, Rossi, Benedetta, Rogers, Helen, Cleave, Barbara, Strom, Michelle, Adelantado, Juan María, Isabel Chico, Ana, Tundidor, Diana, Malcolm, Janine, Henry, Kathy, Morris, Damian, Rayman, Gerry, Fowler, Duncan, Mitchell, Susan, Rosier, Josephine, Temple, Rosemary, Turner, Jeremy, Canciani, Gioia, Hewapathirana, Niranjala, Piper, Leanne, Kudirka, Anne, Watson, Margaret, Bonomo, Matteo, Pintaudi, Basilio, Bertuzzi, Federico, Daniela, Giuseppina, Mion, Elena, Lowe, Julia, Halperin, Ilana, Rogowsky, Anna, Adib, Sapida, Lindsay, Robert, Carty, David, Crawford, Isobel, Mackenzie, Fiona, McSorley, Therese, Booth, John, McInnes, Natalia, Smith, Ada, Stanton, Irene, Tazzeo, Tracy, Weisnagel, John, Mansell, Peter, Jones, Nia, Babington, Gayna, Spick, Dawn, MacDougall, Malcolm, Chilton, Sharon, Cutts, Terri, Perkins, Michelle, Scott, Eleanor, Endersby, Del, Dover, Anna, Dougherty, Frances, Johnston, Susan, Heller, Simon, Novodorsky, Peter, Hudson, Sue, Nisbet, Chloe, Ransom, Thomas, Coolen, Jill, Baxendale, Darlene, Holt, Richard, Forbes, Jane, Martin, Nicki, Walbridge, Fiona, Dunne, Fidelma, Conway, Sharon, Egan, Aoife, Kirwin, Collette, Maresh, Michael, Kearney, Gretta, Morris, Juliet, Quinn, Susan, Bilous, Rudy, Mukhtar, Rasha, Godbout, Ariane, Daigle, Sylvie, Lubina, Alexandra, Jackson, Margaret, Paul, Emma, Taylor, Julie, Houlden, Robyn, Breen, Adriana, Banerjee, Anita, Brackenridge, Anna, Briley, Annette, Reid, Anna, Singh, Claire, Newstead-Angel, Jill, Baxter, Janet, Philip, Sam, Chlost, Martyna, Murray, Lynne, Castorino, Kristin, Frase, Donna, Lou, Olivia, Pragnell, Marlon, Feig, Denice S, Donovan, Lois E, Corcoy, Rosa, Murphy, Kellie E, Amiel, Stephanie A, Hunt, Katharine F, Asztalos, Elizabeth, Barrett, Jon F R, Sanchez, J Johanna, de Leiva, Alberto, Hod, Moshe, Jovanovic, Lois, Keely, Erin, McManus, Ruth, Hutton, Eileen K, Meek, Claire L, Stewart, Zoe A, Wysocki, Tim, O'Brien, Robert, Ruedy, Katrina, Kollman, Craig, Tomlinson, George, and Murphy, Helen R

Published
2017
Full Text
View/download PDF

6. Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS

Author

Miller, Timothy M, Cudkowicz, Merit E, Andrews, Jinsy A, Hesters, Adele, Kermorvant, Hugo, Lacomblez, Lucette, Forestier, Nadine Le, Lenglet, Thimotée, Retail, Maryvonne, Ruiz Del Mar Amador, Maria, Salachas, François, Shotar, Eimad, Sourour, Nader, Babu, Suma, Dorst, Johannes, Froehlich, Elke, Fromm, Andrea, Kandler, Katharina, Langer, Eva, Leichtle, Sarah, Ludolph, Albert, Mayer, Kristina, Michels, Sebastian, Raubold, Sabine, Benatar, Michael, Schuster, Joachim, Weiland, Ulrike, Wiesenfarth, Maximilian, Witzel, Simon, Calvo, Andrea, Canosa, Antonio, Casale, Federico, Chiò, Adriano, Fuda, Giuseppe, Grassano, Maurizio, McDermott, Christopher J, Marchese, Giulia, Moglia, Cristina, Palumbo, Francesca, Salamone, Paolina, Ajiki, Takahiro, Akasaka, Aya, Ando, Masahiro, Arata, Hitoshi, Asuka, Kitamura, Baba, Kosuke, Cochrane, Thos, Bekku, Goichi, Chiba, Tomoya, Date, Yugaku, Eriko, Takeuchi, Hashiguchi, Akihiro, Hatatori, Ritsuko, Hayano, Eri, Hayashi, Yuto, Higashi, Keiko, Higuchi, Eriko, Chary, Sowmya, Hiramatsu, Yu, Horikawa, Rui, Ikenaka, Kensuke, Ishiura, Hiroyuki, Ito, Daisuke, Kawai, Sachiko, Kikuchi, Junko, Kuzuyama, Haruko, Li, Xuehong, Matsumoto, Chika, Chew, Sheena, Matsuura, Eiji, Michizono, Kumiko, Mitsui, Jun, Mitsutake, Akihiko, Mochizuki, Hideki, Nagamatsu, Akemi, Nagano, Seiichi, Nakamura, Tomonori, Naruse, Hiroya, Ogasawara, Asuka, Zhu, Han, Okada, Kensuke, Okamoto, Yuji, Okuno, Tatsusada, Oyama, Satoshi, Ozono, Tatsuhiko, Sakiyama, Yusuke, Sakuishi, Kaori, Seki, Morinobu, Shibata, Shota, Shimizu, Mikito, Wu, Fan, Takahata, Katsunori, Takahito, Yoshizaki, Takashima, Hiroshi, Takeichi, Hiroko, Tashiro, Yuichi, Toda, Tatsushi, Tomizu, Yuki, Tomoya, Wadayama, Ujiakira, Nishiike, Yashita, Daiki, Nestorov, Ivan, Al-Chalabi, Ammar, Alix, James, Bangalore, Priyadarshini, Blackburn, Daniel, Chiwera, Theresa, Clegg, Rosie, Collins, Alexis, Cooper-Knock, Jonathan, Emery, Anna, Franklin, John, Genge, Angela, Graham, Danielle, Green, Louisa, Harvey, Callum, Hobson, Esther, Islam, Mahjabim, Jenkins, Thomas Michael, Kazoka, Mbombe, Kelly, Gillian, Korley, Mercy, Madarshahaian, Daniel, Mayl, Keith, Sun, Peng, McDermott, Christopher John, Radford, Alex, Shaw, Christopher, Shaw, Pamela J, Sidebottom, Joe, Smart, Lynne, Sreedharan, Jemeen, Stone, Ben, Tsironis, Theocharis, Tuddenham, Lee, McNeill, Manjit, Verber, Nick, Wollff, Helen, Young, Stacy, Zis, Panagiotis, Adamo, Ashley, Ahmed, Arubah, Ajroud-Driss, Senda, Alameda, Gustave, Arcila-Londono, Ximena, Fanning, Laura, Baird, Candy, Bazan, Tracy, Berry, James, Bordeau, Jane, Bradford, Wendy, Brook, Nyda, Brown, Lauren, Bucelli, Robert C, Ferguson, Toby A, Buckner, Katherine, Budler, Michael W, Burba, Lindita, Burke, Katherine, Calhoun, Ashley D, Campbell, Sarah, Carey, Judith, Caristo, Irys B, Carty, Simon, Chan, Emmanuel, Fradette, Stephanie, Chaudhry, Vinay, Chen, Ricky, Chow, Saephanh, Clawson, Lora L, Clemens, Mitchell, Cloninger, Suzann E, Coleman-Wood, Krista, Cooper, Thomas N, Cummings, Arlena, Daniels, Jacquelyn, VALOR, DeSaro, Pamela, DeWitt, Michelle, Dedi, Brixhilda, Dempsey, Debbie, Denny, Carol, Doherty, Jenna, Doherty, Leana, Donahue, Megan, Doyle, Michael, Duncan, Jessie, Group, OLE Working, Elman, Lauren, Eloge, Christine M, Echiti, Desirae R, Ferrey, Dominic, Fournier, Christina, Fukumura, Yuriko, Gallagher, Katherine, Garaycoa, Jessica, Garrett, Mark, Gibson, Richard L, Beullens, Lien, Gifford, Ryan, Glass, Jonathan D, Gogol, Danuta, Golden, Shea, Gonzalez, Alexa, Goodman, Ira, Goolsby, Christopher, Goslin, Kimberly, Goulbourne, Michael, Granit, Volkan, Claeys, Kristl, Grignon, Anne-Laure, GuhaRay, Adreeja, Guide, Debra, Gundogdu, Melek Betul, Gutierrez, Gil, Hastings, Debbie, Hayzen, Colleen, Herzog, Hilary, Holloway, Raegan, Jacobs, Gabriel, Claeys, Thomas, Jacobsen, Bill, James, Virginia, Jenkins, Liberty, Jockel-Balsarotti, Jennifer, Johnson, Linda Carol, Jose, Sunil, Joslin, Benjamin, Karanja, Elizabeth, Katz, Jonathan, Keener, Anthony, Couwelier, Goedele, Kittle, Gale, Klein, Sara, Kreple, Collin, Rebecca, Rebecca, Kuenzler, Kuenzler, Kusnir, Jorge, Labbe, Kristen, Lachica-Encinas, Nicolet, Ladha, Shafeeq, Leimer, Lesli, D'Hondt, Ann, Levy, Michael, Levy, Wendy, Li, Yingji, Likanje, Marie-France, Livigni, Rebecca, Locatelli, Eduardo, Luppino, Sarah, Malcolm, Amber, Maragakis, Nicholas, Marin, Horia, Debien, Elisa, Markowitz, Clyde, Markway, Jesse, McCaffrey, Alexandra, McCoy, Arita, McCoy Gross, Kelly, Mehta, Kush, Meyer, Robert, Milan, Jennifer, Miller, Timothy, Miller, Robert G, de Keersmaecker, Sebastiaan, Morales, Francisco, Mosmiller, Elizabeth, Mott, Donovan, Moulton, Kelsey, Murphy, Christine A, Negron, Tirso, Nelson, Cassandra, Newman, Daniel S, Nissinen, Janne Kristoffer, Norman, Andrew, Della Faille, Laetitia, Ohkubo, Takuya, Olney, Nicholas, Ortiz, Natasha, Oskarsson, Bjorn, Pace, Mitchell, Packard, Kathleen, Padgett, Denny, Paganoni, Sabrina, Paredes, Maria E, Parker, Elizabeth, Delmotte, Koen, Partlow, Ann, Pattee, Gary L, Paulett, Jany, Pelot, Antoinette, Pfeifer, Kyle M, Pijanowski, Olivia, Pioro, Erik, Polak, Meraida, Prakash, Ahalya, Previte, Rosemarie, Depoortere, Sofie, Pukenas, Bryan, Quinn, Colin, Ravits, John, Razavi, Ryan, Regan, Tyler, Riley, Kristen M, Roth, Heather, Sanders, Danica, Scalia, Jennifer, Schmidt, Emma, de Velder, Laura, Schwen, Edward, Shah, Jaimin, Shah, Stuti, Shefner, Jeremy, Sheldon, Danielle, Simmons, Karon, Singh, Navneet K, Singleton, Jessica, Smiley, Richard, Smith, William B, Dobbels, Laurens, Smith, Sean, Sotirchos, Elias, Sorenson, Eric, Staff, Nathan, Steele, Julie, Steijlen, Kara, Stirrat, Taylor, Stoica, George S, Strong, Stephanie, Sufit, Robert, Sobue, Gen, Gijs, Jeroen, Sultze, Jane, Swartz, Amy, Szymanski, April, Tay, Anna, Thakore, Nimish, Thiessen, Diana, Thotala, Sukrutha, Trudell, Randall G, Turcotte, Nicole, Turner, Michelle, Horckmans, Simon, Uchil, Alpa, Upadhyay, Vihar, Usman, Uzma, Vallis, Anne, Vaporean-Bussey, Danielle, Vladimirova, Valentine, Weber, Harli, Winbigler, Jennifer, Wojanowski, Heather, Wulf, Charlie, Lamaire, Nikita, Yasek, Julia, Yoo, Stephanie, Zivalic, Hannah, Cole, Alexandra, File, Greta, Foate, Jeremy, Mason, Deborah, Newton, Susan, Roberts, Stephen, Sellwood, Cory Dean, Liessens, Hannelore, Swan, James, Werno, Anja, Zhong, Cathy, Masrori, Pegah, Nysten, Celine, Schotte, Caroline, Serrien, Anouk, Swinnen, Bart, Tilkin, Petra, van Daele, Sien, Van Damme, Philip, Vynckier, Jan, Wouters, Anke, Abrahao, Agessandro, Angle, Mark, Badawy, Mohamed, Berube, Maxime, Bertone, Vanessa, Cooper, Sarah Marie, Dobrowolski, Peter, Fong, Helen, Hannouche, Matthew, Hartley, Denise, Hogan, Michael, Johnston, Wendy, Khalfallah, Yousra, Korngut, Lawrence, Kroetsch, Gina, Letourneau, Justin, Magnussen, Claire, Martinez, Jose, Massie, Rami, Mobach, Theodore, Mookshah, Jahan, Ozelsel, Timur, Parks, Andrea, Petrillo, Janet, Pfeffer, Gerald, Ludolph, Albert C, Pham, Shirley, Phung, Liane, Shiungsun, Rodney, Pi-Shan, Li, Santos, Denizart, Salmon, Kristiana, Saunders, Natalie, Sembinelli, Dylan, Tymkow, Kelsey, Wong, Berchman, Zinman, Lorne, Karlsborg, Merete, Pedersen Lomholt, Therese, Nilsson, Sigrid, Salvesen, Lisette, Skov, Pernille, Svenstrup, Kristen, Bruneteau, Gaelle, Calerencon, Frederic, and Guimaraes Costa, Raquel

Subjects
Adult, drug effects [Recovery of Function], Spinal, Oligonucleotides, blood [Neurofilament Proteins], administration & dosage [Oligonucleotides, Antisense], tofersen, Injections, blood [Amyotrophic Lateral Sclerosis], pharmacology [Oligonucleotides, Antisense], Superoxide Dismutase-1, Double-Blind Method, Neurofilament Proteins, Humans, ddc:610, Antisense, Injections, Spinal, Biomarkers, Recovery of Function, Amyotrophic Lateral Sclerosis, Oligonucleotides, Antisense, blood [Biomarkers], drug therapy [Amyotrophic Lateral Sclerosis], therapeutic use [Oligonucleotides, Antisense], SOD1 protein, human, General Medicine, genetics [Superoxide Dismutase-1], genetics [Amyotrophic Lateral Sclerosis], cerebrospinal fluid [Biomarkers], cerebrospinal fluid [Superoxide Dismutase-1], cerebrospinal fluid [Amyotrophic Lateral Sclerosis]
Abstract

The intrathecally administered antisense oligonucleotide tofersen reduces synthesis of the superoxide dismutase 1 (SOD1) protein and is being studied in patients with amyotrophic lateral sclerosis (ALS) associated with mutations in SOD1 (SOD1 ALS).In this phase 3 trial, we randomly assigned adults with SOD1 ALS in a 2:1 ratio to receive eight doses of tofersen (100 mg) or placebo over a period of 24 weeks. The primary end point was the change from baseline to week 28 in the total score on the ALS Functional Rating Scale-Revised (ALSFRS-R; range, 0 to 48, with higher scores indicating better function) among participants predicted to have faster-progressing disease. Secondary end points included changes in the total concentration of SOD1 protein in cerebrospinal fluid (CSF), in the concentration of neurofilament light chains in plasma, in slow vital capacity, and in handheld dynamometry in 16 muscles. A combined analysis of the randomized component of the trial and its open-label extension at 52 weeks compared the results in participants who started tofersen at trial entry (early-start cohort) with those in participants who switched from placebo to the drug at week 28 (delayed-start cohort).A total of 72 participants received tofersen (39 predicted to have faster progression), and 36 received placebo (21 predicted to have faster progression). Tofersen led to greater reductions in concentrations of SOD1 in CSF and of neurofilament light chains in plasma than placebo. In the faster-progression subgroup (primary analysis), the change to week 28 in the ALSFRS-R score was -6.98 with tofersen and -8.14 with placebo (difference, 1.2 points; 95% confidence interval [CI], -3.2 to 5.5; P = 0.97). Results for secondary clinical end points did not differ significantly between the two groups. A total of 95 participants (88%) entered the open-label extension. At 52 weeks, the change in the ALSFRS-R score was -6.0 in the early-start cohort and -9.5 in the delayed-start cohort (difference, 3.5 points; 95% CI, 0.4 to 6.7); non-multiplicity-adjusted differences favoring early-start tofersen were seen for other end points. Lumbar puncture-related adverse events were common. Neurologic serious adverse events occurred in 7% of tofersen recipients.In persons with SOD1 ALS, tofersen reduced concentrations of SOD1 in CSF and of neurofilament light chains in plasma over 28 weeks but did not improve clinical end points and was associated with adverse events. The potential effects of earlier as compared with delayed initiation of tofersen are being further evaluated in the extension phase. (Funded by Biogen; VALOR and OLE ClinicalTrials.gov numbers, NCT02623699 and NCT03070119; EudraCT numbers, 2015-004098-33 and 2016-003225-41.).

Published
2022
Full Text
View/download PDF

8. Long-Term Follow-up of AUTO1, a Fast-Off Rate CD19 CAR, in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia and Factors Associated with Durable Response

Author

Roddie, Claire, primary, Dias, Juliana, additional, O’Reilly, Maeve, additional, Mitsikakou, Marina, additional, Charalambous, Eftychia, additional, Green, Louisa, additional, Vaughn, Mhairi, additional, Agliardi, Giulia, additional, Garcia, John, additional, Lewin, Evie, additional, Lowdell, Mark, additional, Marzolini, Maria, additional, Holmes, Helen, additional, Ngai, Yenting, additional, Popova, Bilyana, additional, Wilson, William, additional, Kunaseelan, Sangeetha, additional, Spanswick, Victoria, additional, Lowe, Helen, additional, Ensell, Leah, additional, Hartley, John, additional, Linch, David, additional, Bloor, Adrian J, additional, Irvine, David, additional, Pule, Martin, additional, and Peggs, Karl S., additional

Published
2023
Full Text
View/download PDF

9. Safety, Efficiency and Long-Term Follow-up of AUTO1, a Fast-Off Rate CD19 CAR in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia and Other B-Cell Malignancies

Author

Roddie, Claire, primary, Dias Alves Pinto, Juliana, additional, O'Reilly, Maeve A, additional, Mitsikakou, Marina, additional, Charalambous, Eftychia, additional, Green, Louisa, additional, Vaughan, Mhairi, additional, Agliardi, Giulia, additional, Garcia, John, additional, Lewin, Evie, additional, Lowdell, Mark W., additional, Marzolini, Maria A V, additional, Wood, Leigh, additional, Holmes, Helen, additional, Ngai, Yenting, additional, Popova, Bilyana, additional, Wilson, William, additional, Kunaseelan, Sangeetha, additional, Spanswick, Victoria, additional, Lowe, Helen, additional, Ensell, Leah, additional, Hartley, John A., additional, Morley, Simon, additional, Linch, David C., additional, Bloor, Adrian, additional, Irvine, David A., additional, Pule, Martin, additional, and Peggs, Karl S, additional

Published
2022
Full Text
View/download PDF

10. Safety and Efficacy of AUTO1, a Fast-Off Rate CD19 CAR in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL) and Chronic Lymphocytic Leukaemia (CLL)

Author

Roddie, Claire, primary, Dias, Juliana, additional, O'Reilly, Maeve A, additional, Cadinanos Garai, Amaia, additional, Green, Louisa, additional, Abbasian, Mahnaz, additional, Mitsikakou, Marina, additional, Vaughan, Mhairi, additional, Meyer Cantinho Pereira, Vitoria, additional, Marzolini, Maria A V, additional, Wood, Leigh, additional, Olejnik, Joanna, additional, Ngai, Yenting, additional, Popova, Bilyana, additional, Wilson, William, additional, Spanswick, Victoria, additional, Lowe, Helen, additional, Ensell, Leah, additional, Hartley, John A., additional, Farzaneh, Farzin, additional, Lowdell, Mark W., additional, Linch, David C., additional, Pule, Martin, additional, and Peggs, Karl S, additional

Published
2021
Full Text
View/download PDF

11. Development of a Phase 1 Study Evaluating the Activity of Modular CAR T for Multiple Myeloma (MCARTY) Targeting BCMA and CD19 for Improved Persistence

Author

Lee, Lydia Sarah Hui, Lim, Wen Chean, Mactier, Catriona, Dias Alves Pinto, Juliana, Pereira, Vitoria, Vaughan, Mhairi, Green, Louisa, Lewin, Evie, Garcia, John, Agliardi, Giulia, Pathak, Yashma, Jannoo, Riaz, Wood, Leigh, Popova, Bilyana, Holmes, Helen, Thomas, Simon, Spanswick, Victoria, Wilson, William, Parrish, Christopher, Popat, Rakesh, Roddie, Claire, Yong, Kwee, and Pule, Martin A.

Published
2023
Full Text
View/download PDF

13. 277 - Long-Term Follow-up of AUTO1, a Fast-Off Rate CD19 CAR, in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia and Factors Associated with Durable Response

Author

Roddie, Claire, Dias, Juliana, O’Reilly, Maeve, Mitsikakou, Marina, Charalambous, Eftychia, Green, Louisa, Vaughn, Mhairi, Agliardi, Giulia, Garcia, John, Lewin, Evie, Lowdell, Mark, Marzolini, Maria, Holmes, Helen, Ngai, Yenting, Popova, Bilyana, Wilson, William, Kunaseelan, Sangeetha, Spanswick, Victoria, Lowe, Helen, Ensell, Leah, Hartley, John, Linch, David, Bloor, Adrian J, Irvine, David, Pule, Martin, and Peggs, Karl S.

Published
2023
Full Text
View/download PDF

16. Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial

Author

Feig, Denice S, Donovan, Lois E, Corcoy, Rosa, Murphy, Kellie E, Amiel, Stephanie A, Hunt, Katharine F, Asztalos, Elizabeth, Barrett, Jon F R, Sanchez, J Johanna, de Leiva, Alberto, Hod, Moshe, Jovanovic, Lois, Keely, Erin, McManus, Ruth, Hutton, Eileen K, Meek, Claire L, Stewart, Zoe A, Wysocki, Tim, O'Brien, Robert, Ruedy, Katrina, Kollman, Craig, Tomlinson, George, Murphy, Helen R, Grisoni, Jeannie, Byrne, Carolyn, Davenport, Katy, Neoh, Sandra, Gougeon, Claire, Oldford, Carolyn, Young, Catherine, Green, Louisa, Rossi, Benedetta, Rogers, Helen, Cleave, Barbara, Strom, Michelle, Adelantado, Juan María, Isabel Chico, Ana, Tundidor, Diana, Malcolm, Janine, Henry, Kathy, Morris, Damian, Rayman, Gerry, Fowler, Duncan, Mitchell, Susan, Rosier, Josephine, Temple, Rosemary, Turner, Jeremy, Canciani, Gioia, Hewapathirana, Niranjala, Piper, Leanne, Kudirka, Anne, Watson, Margaret, Bonomo, Matteo, Pintaudi, Basilio, Bertuzzi, Federico, Daniela, Giuseppina, Mion, Elena, Lowe, Julia, Halperin, Ilana, Rogowsky, Anna, Adib, Sapida, Lindsay, Robert, Carty, David, Crawford, Isobel, Mackenzie, Fiona, McSorley, Therese, Booth, John, McInnes, Natalia, Smith, Ada, Stanton, Irene, Tazzeo, Tracy, Weisnagel, John, Mansell, Peter, Jones, Nia, Babington, Gayna, Spick, Dawn, MacDougall, Malcolm, Chilton, Sharon, Cutts, Terri, Perkins, Michelle, Scott, Eleanor, Endersby, Del, Dover, Anna, Dougherty, Frances, Johnston, Susan, Heller, Simon, Novodorsky, Peter, Hudson, Sue, Nisbet, Chloe, Ransom, Thomas, Coolen, Jill, Baxendale, Darlene, Holt, Richard, Forbes, Jane, Martin, Nicki, Walbridge, Fiona, Dunne, Fidelma, Conway, Sharon, Egan, Aoife, Kirwin, Collette, Maresh, Michael, Kearney, Gretta, Morris, Juliet, Quinn, Susan, Bilous, Rudy, Mukhtar, Rasha, Godbout, Ariane, Daigle, Sylvie, Lubina, Alexandra, Jackson, Margaret, Paul, Emma, Taylor, Julie, Houlden, Robyn, Breen, Adriana, Banerjee, Anita, Brackenridge, Anna, Briley, Annette, Reid, Anna, Singh, Claire, Newstead-Angel, Jill, Baxter, Janet, Philip, Sam, Chlost, Martyna, Murray, Lynne, Castorino, Kristin, Frase, Donna, Lou, Olivia, and Pragnell, Marlon

Subjects
endocrine system diseases
Abstract

Background: \ud Pregnant women with type 1 diabetes are a high-risk population who are recommended to strive for optimal glucose control, but neonatal outcomes attributed to maternal hyperglycaemia remain suboptimal. Our aim was to examine the effectiveness of continuous glucose monitoring (CGM) on maternal glucose control and obstetric and neonatal health outcomes.\ud \ud Methods: \ud In this multicentre, open-label, randomised controlled trial, we recruited women aged 18–40 years with type 1 diabetes for a minimum of 12 months who were receiving intensive insulin therapy. Participants were pregnant (≤13 weeks and 6 days' gestation) or planning pregnancy from 31 hospitals in Canada, England, Scotland, Spain, Italy, Ireland, and the USA. We ran two trials in parallel for pregnant participants and for participants planning pregnancy. In both trials, participants were randomly assigned to either CGM in addition to capillary glucose monitoring or capillary glucose monitoring alone. Randomisation was stratified by insulin delivery (pump or injections) and baseline glycated haemoglobin (HbA1c). The primary outcome was change in HbA1c from randomisation to 34 weeks' gestation in pregnant women and to 24 weeks or conception in women planning pregnancy, and was assessed in all randomised participants with baseline assessments. Secondary outcomes included obstetric and neonatal health outcomes, assessed with all available data without imputation. This trial is registered with ClinicalTrials.gov, number NCT01788527.\ud \ud Findings: \ud Between March 25, 2013, and March 22, 2016, we randomly assigned 325 women (215 pregnant, 110 planning pregnancy) to capillary glucose monitoring with CGM (108 pregnant and 53 planning pregnancy) or without (107 pregnant and 57 planning pregnancy). We found a small difference in HbA1c in pregnant women using CGM (mean difference −0·19%; 95% CI −0·34 to −0·03; p=0·0207). Pregnant CGM users spent more time in target (68% vs 61%; p=0·0034) and less time hyperglycaemic (27% vs 32%; p=0·0279) than did pregnant control participants, with comparable severe hypoglycaemia episodes (18 CGM and 21 control) and time spent hypoglycaemic (3% vs 4%; p=0·10). Neonatal health outcomes were significantly improved, with lower incidence of large for gestational age (odds ratio 0·51, 95% CI 0·28 to 0·90; p=0·0210), fewer neonatal intensive care admissions lasting more than 24 h (0·48; 0·26 to 0·86; p=0·0157), fewer incidences of neonatal hypoglycaemia (0·45; 0·22 to 0·89; p=0·0250), and 1-day shorter length of hospital stay (p=0·0091). We found no apparent benefit of CGM in women planning pregnancy. Adverse events occurred in 51 (48%) of CGM participants and 43 (40%) of control participants in the pregnancy trial, and in 12 (27%) of CGM participants and 21 (37%) of control participants in the planning pregnancy trial. Serious adverse events occurred in 13 (6%) participants in the pregnancy trial (eight [7%] CGM, five [5%] control) and in three (3%) participants in the planning pregnancy trial (two [4%] CGM and one [2%] control). The most common adverse events were skin reactions occurring in 49 (48%) of 103 CGM participants and eight (8%) of 104 control participants during pregnancy and in 23 (44%) of 52 CGM participants and five (9%) of 57 control participants in the planning pregnancy trial. The most common serious adverse events were gastrointestinal (nausea and vomiting in four participants during pregnancy and three participants planning pregnancy).\ud \ud Interpretation: \ud Use of CGM during pregnancy in patients with type 1 diabetes is associated with improved neonatal outcomes, which are likely to be attributed to reduced exposure to maternal hyperglycaemia. CGM should be offered to all pregnant women with type 1 diabetes using intensive insulin therapy. This study is the first to indicate potential for improvements in non-glycaemic health outcomes from CGM use.\ud \ud Funding: \ud Juvenile Diabetes Research Foundation, Canadian Clinical Trials Network, and National Institute for Health Research.

Published
2017

18. Teen's view of AIDS

Author

Green, Louisa

Subjects
Ethnic, cultural, racial issues/studies, Regional focus/area studies
Abstract

Windspeaker Columnist LLOYDMINSTER, Sask. So you grew up in a rural community and think that horrible things like war, disease and hunger that you hear about on the national news [...]

Published
1999

19. Public and private in social life

Author

Green, Louisa Bertch

Subjects
Public and Private in Social Life (Book) -- Book reviews, Books -- Book reviews
Published
1986

20. Privacy

Author

Green, Louisa Bertch

Subjects
Privacy (Book) -- Book reviews, Books -- Book reviews
Published
1986

21. The Power of Public Ideas

Author

Green, Louisa Bertch

Subjects
The Power of Public Ideas (Book) -- Book reviews, Books -- Book reviews
Published
1989

24. Development of an anti-CD2/CD3/CD28 bead-based T-cell proliferation assay.

Author

Green, Louisa

Subjects
*T cells, *CELL proliferation, *CD2 antigen, *CD3 antigen, *CD28 antigen, *SEVERE combined immunodeficiency, *DIAGNOSIS
Abstract

Severe combined immunodeficiency (SCID) has many phenotypes, including those which result in the formation of T cells but render them incapable of an optimal level of proliferation following stimulation by an antigen. Phytohaemagglutinin (PHA) is a mitogen commonly used to assess T-cell proliferation, although anti-CD2/CD3/CD28-coated beads may provide a more physiological trigger. Some patients and healthy controls display poor T-cell proliferation (<45%) in response to PHA, but may be capable of an increased percentage proliferation when stimulated by another mitogen. This study aimed to develop an anti-CD2/CD3/CD28 bead-based T-cell proliferation assay and to compare T-cell proliferation generated by two mitogens both in healthy controls and in poor responders to PHA. A bead-based T-cell proliferation assay was optimized and validated. Peripheral blood mononuclear cells (PBMCs) were extracted from whole blood samples of 10 healthy controls and 3 poor PHA responders. PBMCs were incubated with carboxyfluorescin diacetate succinimidyl ester and three separate stimulants: PHA, Beads only and Beads plus IL-2. Flow cytometry was performed on Day 6, following fluorochrome staining with CD3 PerCP and CD4 APC, to identify CD4+ T cells. No significant difference was found between the results generated by PHA- or Bead stimulation in 10 healthy controls. A strong positive correlation was observed between the use of the Beads alone and the addition of IL-2. A varied response to the Beads was produced among the poor PHA responders. It has been concluded that the bead-based assay will be run alongside every PHA test in the Oxford Immunology diagnostic laboratory. The step to add IL-2 on Day 3 will not be included as this did not significantly impact T-cell proliferation. The Bead assay provides a more physiological addition to the current PHA test and may be useful in assessing T-cell proliferation in those patients who respond poorly to PHA. However, some individuals who respond poorly to PHA may also respond poorly to the anti-CD2/CD3/CD28 Beads. [ABSTRACT FROM PUBLISHER]

Published
2014
Full Text
View/download PDF

27. EXPECTATION.

Author

GREEN, LOUISA M.

Subjects
EXPECTATION (Poem), GREEN, Louisa M.
Abstract

The poem "Expectation," by Louisa M. Green. First Line: Why comes he not? He should have come ere this: Last Line: Warm heart; he comes--to clasp his bride.

Published
1848

28. Reflections on Stockwell Depot

Author

Waterworth, David, Waterworth, David, Cornish, Sam, Green, Louisa, and Hale, Ann M.

Subjects
NB
Abstract

The following text combines selected extracts from interviews held separately between 2013-14 with ten of the artists associated with Stockwell Depot. This selection addresses core issues associated with the Depot during 1967-79, a period in which each of these artists had an active involvement. David Evison, Gerard Hemsworth and Peter Hide helped to set up the studios in 1967; John Mclean moved into an area managed by Evison by 1970; Jennifer Durrant, Katherine Gili and Anthony Smart all first sublet from Hide in the early 1970s; and Mark Skilton arrived later in that decade. From 1975-79 the annual Stockwell Depot exhibitions regularly included a number of artists, including Alan Gouk and Paul Tonkin, who did not have studio spaces in the building.

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results